Join Us

2020 European Society for Medical Oncology Congress Coverage

Save as Favorite
Sign in to receive recommendations (Learn more)

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.

Research News

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative Breast Cancer

Adding Tecentriq to Chemotherapy Before Surgery for Early-Stage Triple-Negative Breast Cancer Improves pCR Rates

Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation

Adding Verzenio to Hormonal Therapy After Surgery for Early-Stage Breast Cancer With High Risk of Recurrence Reduces That Recurrence Risk

Podcast Episodes

Does Chemotherapy Choice Affect How Well Tecentriq Works Against Breast Cancer?
Leisha Emens, M.D., Ph.D.

Breast Cancer Research at ESMO 2020
Michael Method, M.D.

Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers
Stephen Johnston, M.D., Ph.D.

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations

How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top